Senior executives from GSK, Bayer, Johnson & Johnson and Novartis, at a recent summit, discussed how things were shaping around leveraging artificial intelligence in clinical trials, areas that have seen traction and also some of the challenges on hand.
GSK’s senior vice president, head of development, Christopher Corsico, said that from the company’s perspective, the “reality” of AI begins...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?